Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension

References

• European Glaucoma SocietyTerminology and guidelines for glaucomaSivona, ItalyDogma2008
   Google Scholar
• WebersCABeckersHJNuijtsRMSchoutenJSPharmacological management of primary open-angle glaucoma: second-line options and beyondDrugs Aging20082572975918729546
   PubMed Web of Science ®Google Scholar
• CoxJAMollanSPBankartJRobinsonREfficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic reviewBr J Ophthalmol20089272973418460539
   PubMed Web of Science ®Google Scholar
• BeckersHJSchoutenJSWebersCAvan der ValkRHendrikseFSide effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfactionGraefes Arch Clin Exp Ophthalmol20082461485149018575878
   PubMed Web of Science ®Google Scholar
• KhouriASRealiniTFechtnerRDUse of fixed-dose combination drugs for the treatment of glaucomaDrugs Aging2007241007101618020533
   PubMed Web of Science ®Google Scholar
• FechtnerRDRealiniTFixed combinations of topical glaucoma medicationsCurr Opin Ophthalmol20041513213515021225
   PubMedGoogle Scholar
• BaudouinCRianchoLWarnetJMBrignoleFIn vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprostInvest Ophthalmol Vis Sci2007484123412817724196
   PubMed Web of Science ®Google Scholar
• KahookMYNoeckerRJComparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tearsCornea20082733934318362664
   PubMed Web of Science ®Google Scholar
• JaenenNBaudouinCPouliquenPManniGFigueiredoAZeyenTOcular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol20071734134917534814
   PubMed Web of Science ®Google Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol20028641842311914211
   PubMed Web of Science ®Google Scholar
• HommerAThygesenJFerrerasAA European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucomaEur J Ophthalmol20081877878618850558
   PubMed Web of Science ®Google Scholar
• FrancisBADuLTBerkeSEhrenhausMMincklerDSComparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol – a randomized controlled trial and a replacement studyJ Clin Pharm Ther20042937538015271105
   PubMed Web of Science ®Google Scholar
• Cosopt® [package insert]Whitehouse Station, NJMerck and Co., Inc.2006
   Google Scholar
• Trusopt® [package insert]Whitehouse Station, NJMerck and Co., Inc.2005
   Google Scholar
• European Agency for the Evaluation of Medical ProductsEuropean public assessment report and product information on Azarga [online]. URL http://www.emea.europa.eu/humandocs/Humans/EPAR/azarga/azarga.htm Accessed February 2, 2009.
   Google Scholar
• Azopt® [package insert]Fort Worth, TXAlcon Laboratories, Inc.2008
   Google Scholar
• Betimol® [package insert]Jacksonville, FLVistakon Pharmaceuticals, LLC2006
   Google Scholar
• Timoptic® [package insert]Whitehouse Station, NJMerck and Co., Inc.2005
   Google Scholar
• Istalol® [package insert]Irvine, CAIsta Pharmaceuticals, Inc.2005
   Google Scholar
• IesterMBrinzolamideExpert Opin Pharmacother2008965366218312166
   PubMed Web of Science ®Google Scholar
• SugrueMFPharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitorsProg Retin Eye Res2000198711210614682
   PubMed Web of Science ®Google Scholar
• HollóGUse of topical carbonic anhydrase inhibition in glaucoma treatmentPharmacotherapy in glaucomaBern, SwitzerlandHans Huber Verlag2000
   Google Scholar
• LiuJHMedeirosFASlightJRWeinrebRNComparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapyOphthalmology200911644945419157559
   PubMed Web of Science ®Google Scholar
• KonstasAGMantzirisDAMaltezosACateEAStewartWCComparison of 24 hour control with Timoptic 0.5% and Timoptic-XE 0.5% in exfoliation and primary open-angle glaucomaActa Ophthalmol Scand19997754154310551296
   PubMedGoogle Scholar
• KumarHSudanRSethiHSSonyPTimolol maleate 0.5% versus timolol maleate in gel forming solution 0.5% (Timolol GFS) in open angle glaucoma in India. Preliminary safety and efficacy studyIndian J Ophthalmol200250212312090082
   PubMedGoogle Scholar
• SheddenALaurenceJTippingREfficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter studyClin Ther20012344045011318078
   PubMed Web of Science ®Google Scholar
• OrzalesiNRossettiLInvernizziTBottoliAAutelitanoAEffect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertensionInvest Ophthalmol Vis Sci2000412566257310937568
   PubMed Web of Science ®Google Scholar
• RojanapongpunPDranceSMMorrisonBJOphthalmic artery flow velocity in glaucomatous and normal subjectsBr J Ophthalmol19937725298435394
   PubMed Web of Science ®Google Scholar
• TielschJMKatzJSommerAQuigleyHAJavittJCHypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessmentArch Ophthalmol19951132162217864755
   PubMed Web of Science ®Google Scholar
• AsraniSZeimerRWilenskyJGieserDVitaleSLindenmuthKLarge diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucomaJ Glaucoma2000913414210782622
   PubMed Web of Science ®Google Scholar
• BergeaBBodinLSvedberghBImpact of intraocular pressure regulation on visual fields in open-angle glaucomaOphthalmology19991069971004discussion 1004–1005.10328403
   PubMed Web of Science ®Google Scholar
• Nouri-MahdaviKHoffmanDColemanALAdvanced Glaucoma Intervention Study. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention StudyOphthalmology20041111627163515350314
   PubMed Web of Science ®Google Scholar
• LiuJHKripkeDFTwaMDTwenty-four-hour pattern of intra-ocular pressure in the aging populationIOVS19994029122917
   PubMed Web of Science ®Google Scholar
• CaprioliJIntraocular pressure fluctuation: an independent risk factor for glaucoma?Arch Ophthalmol20071251124112517698763
   PubMedGoogle Scholar
• CareniniABSibourGBoles CareniniBDifferences in the longterm effect of timolol and betaxolol on the pulsatile ocular blood flowSurv Ophthalmol199438SupplS118S1247940133
   PubMedGoogle Scholar
• LubeckPOrgulSGugletaKGherghelDGekkievaMFlammerJEffect of timolol on anterior optic nerve blood flow in patients with primary open-angle glaucoma as assessed by the Heidelberg retina flowmeterJ Glaucoma200110131711219633
   PubMed Web of Science ®Google Scholar
• HarrisASpaethGLSergottRCKatzLJCantorLBMartinBJRetrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucomaAm J Ophthalmol19951201681757639300
   PubMed Web of Science ®Google Scholar
• YoshidaAOgasawaraHFujioNComparison of short- and long-term effects of betaxolol and timolol on human retinal circulationEye19981284885310070522
   PubMed Web of Science ®Google Scholar
• LiuJHLiRNelsonTRWeinrebRNResistance to blood flow in the rabbit ophthalmic artery after topical treatment with timololJ Ocul Pharmacol Ther20072310310917444797
   PubMed Web of Science ®Google Scholar
• SieskyBHarrisASinesDA comparative analysis of the effects of the fixed combination of timolol and dorzolamide versus latanoprost plus timolol on ocular hemodynamics and visual function in patients with primary open-angle glaucomaJ Ocul Pharmacol Ther20062235336117076630
   PubMed Web of Science ®Google Scholar
• BrogliattiBRolleTVizzeriGMCipulloDComparison of the efficacy on intraocular pressure and retinal blood flow of a beta-blocker (timolol maleate) against the fixed association of a topical carbonic anhydrase (dorzolamide) and a beta-blocker (timolol maleate)Acta Ophthalmol Scand20002324749
   Google Scholar
• RolleTTofaniFBrogliattiBGrignoloFMThe effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open-angle glaucoma patientsEye2008221172117918202708
   PubMed Web of Science ®Google Scholar
• MartínezASánchezMA comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in perviously untreated glaucoma patientsCurr Med Res Opin200622677316393432
   PubMed Web of Science ®Google Scholar
• UvaMGLongoAReibaldiMReibaldiAThe effect of timolol-dorzolamide and timolol-pilocarpine combinations on ocular blood flow in patients with glaucomaAm J Ophthalmol20061411158116016765700
   PubMed Web of Science ®Google Scholar
• JanulevicinëIHarrisAKagemannLSieskyBMcCranorLA comparison of theeffects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patientsActa Ophthalmol Scand20048273073715606472
   PubMedGoogle Scholar
• HarrisAJonescu-CuypersCPKagemannLEffect of dorzol-amide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucomaAm J Ophthalmol200113249049511589868
   PubMed Web of Science ®Google Scholar
• BarnesGELiBDeanTChandlerMLIncreased optic nerve head blood flow after 1week of twice daily topical brinzolamide treatment in Dutch-belted rabbitsSurv Ophthalmol200044Suppl 2S131S14010665515
   PubMed Web of Science ®Google Scholar
• IesterMAltieriMMichelsonGVittonePTraversoCECalabriaGRetinal peripapillary blood flow before and after topical brinzolamideOphthalmologica200421839039615564757
   PubMed Web of Science ®Google Scholar
• SieskyBHarrisACantorLBA comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucomaBr J Ophthalmol20089250050418369067
   PubMed Web of Science ®Google Scholar
• KaupMPlangeNNiegelMRemkyAArendOEffects of brinzolamide on ocular haemodynamics in healthy volunteersBr J Ophthalmol20048825726214736787
   PubMed Web of Science ®Google Scholar
• KlemmMZeitzOReussJMatthiessenETRichardGTherapy of normal tension glaucoma: effect of brinzolamide on ocular haemodynamicsKlin Monatsbl Augenheilkd200322033033312766822
   PubMed Web of Science ®Google Scholar
• van der ValkRWebersCASchoutenJSIntraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trialsOphthalmology20051121177118515921747
   PubMed Web of Science ®Google Scholar
• WebersCAvan der ValkRSchoutenJSIntraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trialsOphthalmology2007114404617070584
   PubMed Web of Science ®Google Scholar
• ShinDAdjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapySurv Ophthalmol200044Suppl 2S163S16810665519
   PubMed Web of Science ®Google Scholar
• MichaudJEFrirenBInternational Brinzolamide Adjunctive Study GroupComparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertensionAm J Ophthalmol200113223524311476685
   PubMed Web of Science ®Google Scholar
• MartinezASanchez SalorioMA comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbair hemodynamics and intraocular pressure in open-angle glaucoma patientsJ Ocul Pharmacol Ther20092523924819348600
   PubMed Web of Science ®Google Scholar
• KabackMScoperSVArzenoGIntraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%Ophthalmology20081151728173418538406
   PubMed Web of Science ®Google Scholar
• ManniGDenisPChewPThe safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertensionJ Glaucoma20091829330019365194
   PubMed Web of Science ®Google Scholar
• VoldSDEvansRMStewartRHWaltersTMallickSA one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertensionJ Ocul Pharmacol Ther20082460160519049301
   PubMed Web of Science ®Google Scholar
• SilverLHOcular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study GroupSurv Ophthalmol200044Suppl 2S141S14510665516
   PubMed Web of Science ®Google Scholar
• TsukamotoHNomaHMukaiSIkedaHMishimaHKThe efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamideJ Ocul Pharmacol Ther20052139539916245966
   PubMed Web of Science ®Google Scholar
• BarnebeyHKwokSYPatients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice settingClin Ther2000221204121211110231
   PubMed Web of Science ®Google Scholar
• MundorfTRauchmanSWilliamsRNotivolRA patient preference comparison of Azarga™ (brinzolamide/timolol fixed combination) vs Cosopt® (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertensionClin Ophthalmol2008262362819668763
   PubMedGoogle Scholar
• JampelHDSchwartzGFRobinALAbramsDAJohnsonEMillerRBPatient preferences for eye drop characteristics: a willingness-to-pay analysisArch Ophthalmol200312154054612695251
   PubMed Web of Science ®Google Scholar